GlassScriptPhysician profile
Lisa A Wirth
NPI 1932171758
$6,542.02
in general payments reported to CMS, 2019-2025
27 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $476 · 2021: $740 · 2022: $1,203 · 2023: $1,431 · 2024: $733 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,604 · Education: $70.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,604.44 |
| Education | $70.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,392.30 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,018.90 | 2021-2025 | Vraylar |
| Alkermes, INC. | $683.69 | 2021-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $350.53 | 2020-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $297.31 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $292.63 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $249.83 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $244.34 | 2019-2025 | Spravato |
| Neos Therapeutics, LP | $237.40 | 2019-2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $222.38 | 2022-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $202.88 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $180.12 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Allergan, INC. | $167.70 | 2019-2020 | |
| Axsome Therapeutics, INC. | $120.93 | 2024-2025 | Auvelity |
| Eisai INC. | $112.87 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $107.45 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $98.52 | 2020-2023 | Aplenzin, Wellbutrin |
| Supernus Pharmaceuticals, INC. | $95.23 | 2022-2025 | Qelbree |
| Lundbeck LLC | $91.96 | 2019-2023 | Rexulti |
| Corium, LLC | $89.90 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $86.65 | 2022-2023 | Belsomra |
| Noven Therapeutics, LLC | $78.20 | 2023-2025 | Xelstrym, Secuado |
| Avanir Pharmaceuticals, INC. | $37.53 | 2019 | |
| Adlon Therapeutics L.P. | $24.91 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $21.79 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.68 | 2021 | |
| Tonix Medicines, INC. | $15.39 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Wirth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.